Researcher profile
Lieuwe de Haan
Affiliations
Organizations
Amsterdam Neuroscienceauthorship · NLAmsterdam University Medical Centersauthorship · NLGGNetauthorship · NLGGZ Rivierduinenauthorship · NLMaastricht University Medical Centreauthorship · NLUniversity Medical Center Utrechtauthorship · NLUniversity of Amsterdamauthorship · NLUtrecht Universityauthorship · NL
Public evidence
8 connected articles
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMCCannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMCFirst-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open AccessThe association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMCDaily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open AccessThe continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open AccessSocial disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open AccessThe contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access
Matched by exact identifiers only. Profile data: Corpus/OpenAlex.